%0 Journal Article
%A Gray, Jhanelle E
%A Villegas, Augusto
%A Daniel, Davey
%A Vicente, David
%A Murakami, Shuji
%A Hui, Rina
%A Kurata, Takayasu
%A Chiappori, Alberto
%A Lee, Ki Hyeong
%A Cho, Byoung Chul
%A Planchard, David
%A Paz-Ares, Luis
%A Faivre-Finn, Corinne
%A Vansteenkiste, Johan F
%A Spigel, David R
%A Wadsworth, Catherine
%A Taboada, Maria
%A Dennis, Phillip A
%A Özgüroğlu, Mustafa
%A Antonia, Scott J
%T Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
%D 2019
%U http://hdl.handle.net/10668/14900
%X In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p  Patients, stratified by age, sex, and smoking history, were randomized (2:1) to receive durvalumab, 10 mg/kg intravenously every 2 weeks, or placebo for up to 12 months. OS was analyzed by using a stratified log-rank test in the intention-to-treat population. Medians and rates at 12, 24, and 36 months were estimated by the Kaplan-Meier method. As of January 31, 2019, 48.2% of patients had died (44.1% and 56.5% in the durvalumab and placebo groups, respectively). The median duration of follow-up was 33.3 months. The updated OS remained consistent with that previously reported (stratified HR = 0.69 [95% CI: 0.55-0.86]); the median OS was not reached with durvalumab but was 29.1 months with placebo. The 12-, 24- and 36-month OS rates with durvalumab and placebo were 83.1% versus 74.6%, 66.3% versus 55.3%, and 57.0% versus 43.5%, respectively. All secondary outcomes examined showed improvements consistent with previous analyses. Updated OS data from PACIFIC, including 3-year survival rates, demonstrate the long-term clinical benefit with durvalumab after chemoradiotherapy and further establish the PACIFIC regimen as the standard of care in this population.
%K Durvalumab
%K NSCLC
%K Overall survival
%K PACIFIC
%K Three-year update
%~